Dodt J, Hunfeld A, Daas A, Buchheit K H
Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany.
Pharmeuropa Bio. 2006 Nov;2006(1):15-22.
For the potency assay of human coagulation factor VII concentrate preparations according to the European Pharmacopoeia (Ph. Eur.) a reference preparation calibrated in International Units (IU) is needed. Currently, the 1st International Standard (97/592, potency: 6.3 IU/ampoule) but no Ph. Eur. reference preparation is available. A collaborative study was run to calibrate a candidate Ph. Eur. Biological Reference Preparation (BRP) for human coagulation factor VII concentrate against the 1st International Standard; the BRP is intended to be used as working standard. A candidate BRP batch 1 was produced from a plasma-derived human factor VII concentrate preparation available on the European market. It fulfilled the requirements of a BRP with regard to precision and homogeneity of fill, residual water content and stability. In addition, the content of activated factor VII was low. Sixteen laboratories from 9 countries participated in the collaborative study. The potency of the candidate BRP was determined using the participants' chromogenic assay based on the Ph. Eur. and their in-house clotting assay, if available. The statistical model used for analysis of the results from most laboratories was the maximum likelihood of the parallel line model following a logarithmic transformation of the responses. In the chromogenic assay, a potency estimate of 8.2 IU/vial (+/-3.7%) was obtained for the candidate BRP. Results from the clotting assay were lower and less homogenous (6.7 IU/vial+/-11.6%). The results from the collaborative study showed that the candidate BRP is suitable as a reference standard for the chromogenic assay according to the Ph. Eur. It was adopted by the Ph. Eur. Commission in March 2006 as official Ph. Eur. BRP for this purpose.
按照欧洲药典(Ph. Eur.)对人凝血因子VII浓缩制剂进行效价测定时,需要一种以国际单位(IU)校准的参比制剂。目前,有第一国际标准品(97/592,效价:6.3 IU/安瓿),但没有欧洲药典参比制剂。开展了一项协作研究,以第一国际标准品为对照校准一种人凝血因子VII浓缩制剂的欧洲药典生物参比制剂(BRP)候选品;该BRP拟用作工作标准品。BRP候选品批次1由欧洲市场上可得的血浆源性人因子VII浓缩制剂制备而成。它在装量的精密度和均匀性、残留水分含量及稳定性方面符合BRP的要求。此外,活化因子VII的含量较低。来自9个国家的16个实验室参与了该协作研究。使用参与者基于欧洲药典的显色测定法及其内部凝血测定法(如可用)来测定BRP候选品的效价。大多数实验室用于分析结果的统计模型是响应值经对数转换后的平行线模型的最大似然法。在显色测定法中,BRP候选品的效价估计值为8.2 IU/瓶(±3.7%)。凝血测定法的结果较低且均匀性较差(6.7 IU/瓶±11.6%)。协作研究结果表明,BRP候选品适合作为欧洲药典显色测定法的参比标准品。它于2006年3月被欧洲药典委员会采用为此目的的官方欧洲药典BRP。